Midostaurin was approved by the US FDA and the European Medicines Agency for both newly diagnosed FLT3-mutated AML and advanced systemic mastocytosis (SM) driven by KIT mutation (11). This evidence concerns the gene FLT3 and systemic mastocytosis.